Literature DB >> 32985737

Prostaglandin F receptor antagonist attenuates LPS-induced systemic inflammatory response in mice.

Toko Maehara1, Fumiyoshi Higashitarumi1, Risa Kondo1, Ko Fujimori1.   

Abstract

Although it is known that prostaglandin (PG) F2α level is elevated in the plasma of patients with sepsis, the roles of PGF2α is still unknown. We aimed to clarify the roles of PGF2α in the regulation of lipopolysaccharide (LPS)-induced systemic inflammation. At 24 hours after LPS administration, neutrophil infiltration in peritoneal cavity, the mRNA expression of pro-inflammatory cytokines such as tumor necrosis factor-α, interleukin (IL)-1β, IL-6, and macrophage inflammatory protein-2, and tissue damages in lung, liver, and kidney were all increased. Inhibition of FP receptors significantly decreased LPS-induced neutrophil infiltration and lowered the mRNA expression of the pro-inflammatory cytokines. At 6 hour after LPS administration, the level of anti-inflammatory cytokine, IL-10 in peritoneal lavage fluid was higher than that in naïve mice. Inhibition of FP receptors in these mice increased IL-10 level further. Stimulation of isolated peritoneal neutrophils by LPS increased the gene expression of IL-10, which was further increased by AL8810 treatment. Administration of an anti-IL-10 antibody antagonized the AL8810-decreased mRNA expression of pro-inflammatory cytokines and tissue damages. These results indicate that inhibition of FP receptors by AL8810 attenuated LPS-induced systemic inflammation in mice via enhanced IL-10 production.
© 2020 Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  FP receptor antagonist; neutrophil; prostaglandin F2α; systemic inflammation

Year:  2020        PMID: 32985737     DOI: 10.1096/fj.202001481R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  3 in total

1.  Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.

Authors:  Najam A Sharif
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

2.  The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson's Disease by Inhibiting the NF-κB/NLRP3 Pathway.

Authors:  Shuhan Liu; Shengxiang Wang; Runze Gu; Na Che; Jing Wang; Jinbo Cheng; Zengqiang Yuan; Yong Cheng; Yajin Liao
Journal:  Front Pharmacol       Date:  2022-06-01       Impact factor: 5.988

3.  Bullatine A exerts anti-inflammatory effects by inhibiting the ROS/JNK/NF-κB pathway and attenuating systemic inflammatory responses in mice.

Authors:  Shuhan Liu; Na Che; Wen Ou; Meichen Yan; Yajin Liao; Yong Cheng
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.